vs
AbCellera Biologics Inc.（ABCL）与雅培（ABT）财务数据对比。点击上方公司名可切换其他公司
雅培的季度营收约是AbCellera Biologics Inc.的255.5倍（$11.5B vs $44.9M）。雅培净利率更高（15.5% vs -19.9%，领先35.4%）。AbCellera Biologics Inc.同比增速更快（788.4% vs 4.4%）。雅培自由现金流更多（$2.6B vs $-44.6M）。过去两年AbCellera Biologics Inc.的营收复合增速更高（112.3% vs 7.2%）
AbCellera Biologics是一家总部位于不列颠哥伦比亚省温哥华的生物科技企业，核心业务是探索与开发抗体治疗药物。该公司凭借 proprietary 技术平台可在60天内开发出医疗应对方案，其单细胞筛选技术平台最早诞生于不列颠哥伦比亚大学，还曾作为核心力量参与美国国防高级研究计划局的大流行预防平台项目。
雅培是总部位于美国伊利诺伊州雅培园的跨国医疗健康企业，业务覆盖美国境外市场药品销售、诊断产品、营养产品及医疗器械等板块，在全球医疗健康领域拥有较高的行业知名度与广泛的市场覆盖。
ABCL vs ABT — 直观对比
营收规模更大
ABT
是对方的255.5倍
$44.9M
营收增速更快
ABCL
高出784.0%
4.4%
净利率更高
ABT
高出35.4%
-19.9%
自由现金流更多
ABT
多$2.7B
$-44.6M
两年增速更快
ABCL
近两年复合增速
7.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $44.9M | $11.5B |
| 净利润 | $-8.9M | $1.8B |
| 毛利率 | — | 57.0% |
| 营业利润率 | -63.7% | 19.6% |
| 净利率 | -19.9% | 15.5% |
| 营收同比 | 788.4% | 4.4% |
| 净利润同比 | 73.9% | -80.8% |
| 每股收益（稀释后） | $-0.03 | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABCLABT
| Q4 25 | $44.9M | $11.5B | ||
| Q3 25 | $9.0M | $11.4B | ||
| Q2 25 | $17.1M | $11.1B | ||
| Q1 25 | $4.2M | $10.4B | ||
| Q4 24 | $5.0M | $11.0B | ||
| Q3 24 | $6.5M | $10.6B | ||
| Q2 24 | $7.3M | $10.4B | ||
| Q1 24 | $10.0M | $10.0B |
净利润ABCLABT
| Q4 25 | $-8.9M | $1.8B | ||
| Q3 25 | $-57.1M | $1.6B | ||
| Q2 25 | $-34.7M | $1.8B | ||
| Q1 25 | $-45.6M | $1.3B | ||
| Q4 24 | $-34.2M | $9.2B | ||
| Q3 24 | $-51.1M | $1.6B | ||
| Q2 24 | $-36.9M | $1.3B | ||
| Q1 24 | $-40.6M | $1.2B |
毛利率ABCLABT
| Q4 25 | — | 57.0% | ||
| Q3 25 | — | 55.4% | ||
| Q2 25 | — | 56.4% | ||
| Q1 25 | — | 56.9% | ||
| Q4 24 | — | 55.0% | ||
| Q3 24 | — | 55.8% | ||
| Q2 24 | — | 55.6% | ||
| Q1 24 | — | 55.2% |
营业利润率ABCLABT
| Q4 25 | -63.7% | 19.6% | ||
| Q3 25 | -851.8% | 18.1% | ||
| Q2 25 | -290.2% | 18.4% | ||
| Q1 25 | -1479.6% | 16.3% | ||
| Q4 24 | -1441.0% | 17.4% | ||
| Q3 24 | -1439.4% | 17.5% | ||
| Q2 24 | -1276.2% | 16.1% | ||
| Q1 24 | -551.5% | 13.9% |
净利率ABCLABT
| Q4 25 | -19.9% | 15.5% | ||
| Q3 25 | -637.8% | 14.5% | ||
| Q2 25 | -203.3% | 16.0% | ||
| Q1 25 | -1077.2% | 12.8% | ||
| Q4 24 | -677.6% | 84.1% | ||
| Q3 24 | -785.4% | 15.5% | ||
| Q2 24 | -504.3% | 12.5% | ||
| Q1 24 | -408.0% | 12.3% |
每股收益（稀释后）ABCLABT
| Q4 25 | $-0.03 | $1.01 | ||
| Q3 25 | $-0.19 | $0.94 | ||
| Q2 25 | $-0.12 | $1.01 | ||
| Q1 25 | $-0.15 | $0.76 | ||
| Q4 24 | $-0.11 | $5.26 | ||
| Q3 24 | $-0.17 | $0.94 | ||
| Q2 24 | $-0.13 | $0.74 | ||
| Q1 24 | $-0.14 | $0.70 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $128.5M | $8.9B |
| 总债务越低越好 | — | $12.9B |
| 股东权益账面价值 | $966.9M | $52.1B |
| 总资产 | $1.4B | $86.7B |
| 负债/权益比越低杠杆越低 | — | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资ABCLABT
| Q4 25 | $128.5M | $8.9B | ||
| Q3 25 | $83.2M | $7.7B | ||
| Q2 25 | $92.4M | $7.3B | ||
| Q1 25 | $159.3M | $6.8B | ||
| Q4 24 | $156.3M | $8.0B | ||
| Q3 24 | $126.6M | $7.8B | ||
| Q2 24 | $148.3M | $7.2B | ||
| Q1 24 | $123.6M | $6.7B |
总债务ABCLABT
| Q4 25 | — | $12.9B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $14.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ABCLABT
| Q4 25 | $966.9M | $52.1B | ||
| Q3 25 | $964.0M | $51.0B | ||
| Q2 25 | $1.0B | $50.6B | ||
| Q1 25 | $1.0B | $48.8B | ||
| Q4 24 | $1.1B | $47.7B | ||
| Q3 24 | $1.1B | $39.8B | ||
| Q2 24 | $1.1B | $39.3B | ||
| Q1 24 | $1.1B | $38.8B |
总资产ABCLABT
| Q4 25 | $1.4B | $86.7B | ||
| Q3 25 | $1.4B | $84.2B | ||
| Q2 25 | $1.4B | $84.0B | ||
| Q1 25 | $1.3B | $81.4B | ||
| Q4 24 | $1.4B | $81.4B | ||
| Q3 24 | $1.4B | $74.4B | ||
| Q2 24 | $1.4B | $73.0B | ||
| Q1 24 | $1.5B | $72.5B |
负债/权益比ABCLABT
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.30× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-34.7M | $3.3B |
| 自由现金流经营现金流 - 资本支出 | $-44.6M | $2.6B |
| 自由现金流率自由现金流/营收 | -99.4% | 22.9% |
| 资本支出强度资本支出/营收 | 21.9% | 6.0% |
| 现金转化率经营现金流/净利润 | — | 1.87× |
| 过去12个月自由现金流最近4个季度 | $-174.1M | $7.4B |
8季度趋势，按日历期对齐
经营现金流ABCLABT
| Q4 25 | $-34.7M | $3.3B | ||
| Q3 25 | $-52.6M | $2.8B | ||
| Q2 25 | $-32.4M | $2.0B | ||
| Q1 25 | $-11.6M | $1.4B | ||
| Q4 24 | $-8.0M | $2.9B | ||
| Q3 24 | $-28.9M | $2.7B | ||
| Q2 24 | $-30.0M | $2.0B | ||
| Q1 24 | $-41.7M | $1.0B |
自由现金流ABCLABT
| Q4 25 | $-44.6M | $2.6B | ||
| Q3 25 | $-61.5M | $2.3B | ||
| Q2 25 | $-45.8M | $1.5B | ||
| Q1 25 | $-22.2M | $933.0M | ||
| Q4 24 | $-23.6M | $2.1B | ||
| Q3 24 | $-47.4M | $2.1B | ||
| Q2 24 | $-50.1M | $1.4B | ||
| Q1 24 | $-65.8M | $627.0M |
自由现金流率ABCLABT
| Q4 25 | -99.4% | 22.9% | ||
| Q3 25 | -687.0% | 20.2% | ||
| Q2 25 | -267.9% | 13.9% | ||
| Q1 25 | -524.0% | 9.0% | ||
| Q4 24 | -468.0% | 19.6% | ||
| Q3 24 | -728.4% | 20.2% | ||
| Q2 24 | -683.8% | 13.8% | ||
| Q1 24 | -661.5% | 6.3% |
资本支出强度ABCLABT
| Q4 25 | 21.9% | 6.0% | ||
| Q3 25 | 99.7% | 4.4% | ||
| Q2 25 | 78.2% | 4.5% | ||
| Q1 25 | 251.1% | 4.7% | ||
| Q4 24 | 309.6% | 6.6% | ||
| Q3 24 | 284.6% | 5.2% | ||
| Q2 24 | 274.6% | 5.1% | ||
| Q1 24 | 242.5% | 4.0% |
现金转化率ABCLABT
| Q4 25 | — | 1.87× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.15× | ||
| Q1 25 | — | 1.07× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 1.64× | ||
| Q2 24 | — | 1.51× | ||
| Q1 24 | — | 0.84× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
